drugset
drugset / Trial / NCT06093698

An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

NCT06093698 ↗

Phase 1 Not yet recruiting 94 enrolled ITabMed Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Timeline

Start
2023-12-01
Primary completion
2026-06-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Anti-EpCAM-CD3 Antibody Protein / enzyme biologic 0.05 ug/kg Intravenous
Subject Recombinant Anti-EpCAM-CD3 Antibody Protein / enzyme biologic 0.15 ug/kg Intravenous
Subject Recombinant Anti-EpCAM-CD3 Antibody Protein / enzyme biologic 0.3 ug/kg Intravenous
Subject Recombinant Anti-EpCAM-CD3 Antibody Protein / enzyme biologic 0.6 ug/kg Intravenous
Subject Recombinant Anti-EpCAM-CD3 Antibody Protein / enzyme biologic 0.9 ug/kg Intravenous
Subject Recombinant Anti-EpCAM-CD3 Antibody Protein / enzyme biologic 1.2 ug/kg Intravenous
Subject Recombinant Anti-EpCAM-CD3 Antibody Protein / enzyme biologic 1.5 ug/kg Intravenous

Indications

No indication recorded.